Bone Biologics Reports Q1 2026 Financial Results with $765,988 Net Loss

Bone Biologics Corporation has reported its financial results for the first quarter of 2026, revealing a net loss of $765,988, a 24.7% decrease from the net loss of $1,017,092 in the same period last year. The company did not generate any revenue during this quarter, consistent with its ongoing status as a clinical-stage entity focused on developing its lead product, NELL-1/DBM, for bone regeneration in spinal fusion. Total operating expenses for the quarter were $805,054, down 22.5% from $1,038,486 in the prior year, primarily due to a significant reduction in research and development costs, which fell from $423,576 to $141,597.

The decrease in research and development expenses is attributed to the timing of clinical trials, as the company prepares for a pivotal clinical study. General and administrative expenses increased slightly by 7.9% to $663,457, compared to $614,910 in the previous year. The company also reported an increase in interest income, which rose to $38,801 from $20,039, reflecting improved cash management. The change in the fair value of the warrant liability showed a gain of $265, compared to a gain of $1,355 in the prior year.

As of March 31, 2026, Bone Biologics had total assets of $4,979,305, a decrease from $5,796,135 at the end of 2025. The company’s cash position also declined, with cash and cash equivalents at $4,530,040, down from $5,334,322 at the end of the previous year. The company has incurred accumulated losses of approximately $88.9 million since its inception and anticipates operating expenditures of $5.4 million over the next twelve months. This raises concerns about its ability to continue as a going concern, as noted by its independent auditors.

Bone Biologics continues to focus on its clinical development efforts, including a multicenter, prospective, randomized pilot clinical study of its NB1 bone graft device, which combines NELL-1 with demineralized bone matrix. The study aims to evaluate the safety and effectiveness of the device in treating degenerative disc disease. The company has entered into various agreements with contract research organizations and contract manufacturing organizations to support this study. However, it has not sold any shares through its At The Market (ATM) offering program during the first quarter of 2026, following a successful sale of shares in the previous year.

Looking ahead, Bone Biologics is actively seeking additional financing to support its operations and product development. The company acknowledges the uncertainty surrounding its ability to secure sufficient funding and the potential need to scale back or discontinue its development programs if cash resources are insufficient. The management remains focused on advancing its clinical trials and obtaining regulatory approvals necessary for commercialization.